A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs DS 8201 (Primary) ; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-Gastric01
- Sponsors Daiichi Sankyo Company
- 20 Nov 2017 According to a Daiichi Sankyo Company media release, the first patient has been enrolled in the study.
- 17 Oct 2017 Status changed from not yet recruiting to recruiting.
- 09 Oct 2017 New trial record